PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors

Maurizio Martini, Giampaolo Tortora, Emilio Bria, Miriam Grazia Ferrara, Ettore D'Argento, Emanuele Vita, Vincenzo Pio Di Noia, Marta Ribelli, Francesco Paolo Damiano, Maria Antonella Cannella, Alessio Stefani, Serena Pilotto, Isabella Sperduti, Sara Pilotto, Michele Milella

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Rapid disease progression in epidermal growth factor receptor (EGFR) non–small-cell lung cancer treated with tyrosine kinase inhibitorss has been associated with concomitant mutations. The status of 4 genes (PTEN, TP53, c-MET, IGFR) was evaluated by immunohistochemistry in 51 tumor blocks, and it was correlated with overall response rate, overall survival, and progression-free survival. We point out that immunohistochemistry could be a valid tool to identify PTEN loss. Moreover, our results have shown worse outcomes in terms of progression-free survival, overall survival, and objective response rate in patients with concomitant EGFR mutation and PTEN loss. Furthermore, the coexistence of PTEN loss and IGFR overexpression identifies a potential prognostic ‘signature’ for a subgroup of patients with particularly poor prognosis.
Lingua originaleEnglish
pagine (da-a)1-10
Numero di pagine10
RivistaClinical Lung Cancer
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Afatinib
  • Erlotinib
  • Gefitinib
  • IGFR
  • MET
  • Osimertinib
  • p53

Fingerprint Entra nei temi di ricerca di 'PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors'. Insieme formano una fingerprint unica.

Cita questo